Ganoderma lucidum: a potent pharmacological macrofungus.

Bhagwan S Sanodiya1, Gulab Singh Thakur, Rakesh K Baghel

  • 1Research and Development Centre, Bisen Biotech and Biopharma Pvt. Ltd., Biotech Research Park, M-7, Laxmipuram, Transport Nagar, Gwalior- 474010 (M.P.) India. psbisen@gmail.com.

Summary

Ganoderma lucidum, known as Ling Zhi, is a mushroom with 400 bioactive compounds offering numerous health benefits. Cultivation is essential to meet global demand for its therapeutic potential.

Related Concept Videos

Fungal Phylum Basidiomycota01:26

Fungal Phylum Basidiomycota

Basidiomycota is a diverse phylum of fungi that includes ecologically significant decomposers such as white rot fungi, symbionts like mycorrhizal fungi, plant pathogens such as rusts and smuts, and edible species like Agaricus bisporus (the common button mushroom). These fungi play crucial roles in nutrient cycling, symbiotic relationships, and even human health. Their defining feature is the basidium, a microscopic club-shaped structure responsible for producing basidiospores.Fruiting Bodies...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).